Clinical Trial Update: Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor [Phase 1]

View source ↗

Summary

Phase 1 study evaluating Tocagen's retroviral replicating vector Toca 511 in combination with the prodrug 5-fluorocytosine for recurrent malignant brain tumors …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Anaplastic Oligoastrocytoma
• Anaplastic Oligodendroglioma
• Glioblastoma Multiforme

Drugs mentioned

• 5-fluorocytosine (5-fluorocytosine)
• Toca 511 (retroviral replicating vector expressing cytosine deaminase)

Snippet

Sponsor: Tocagen Inc. | Conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1 | Status: COMPLETED